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Dendritic cell-based cancer
immunotherapy: the stagnant
approach and a theoretical solution§
Vladimir M. Subbotin
Anticancer dendritic cells (DC) therapy currently uses in vitro propagation of the patient’s DC and
pulsing with tumor antigens. However, clinical achievements are far from desirable. Here, I suggest that
the lack of anticipated responses could be because cancer cells continuously mutate, whereas the
population of tumor antigens from the excised tumor is genetically static, and because there is an
absence of biologic mechanisms to facilitate intratumoral DC retention, which is needed for DC pulsing.
I hypothesize that stable tumor transfection with fetal liver tyrosine kinase 3 ligand (Flt3-L) and
granulocyte–macrophage colony-stimulating factor (GM-CSF) DNAs will induce homing, propagation
and maturation of intratumoral DC. This must be followed by drug-induced apoptosis of tumor cells, to
ensure the release of tumor antigens for DC pulsing. Then, regardless of any mutation of tumor cells, they
would always incite DC propagation and maturation, pulsing and antitumor immunity.
PERSPECTIVE Drug Discovery Today  Volume 19, Number 7  July 2014Four decades ago, a new cancer treatment
(immunotherapy) was introduced. The impor-
tant methodology of solid cancer immu-
notherapy is intervention based on DC therapy,
the approach envisioned by the Nobel Prize
winner Ralph Steinman and his colleagues [1].
Because of this phenomenon, a treatment
strategy with tumor-specific pulsed DC was
implemented [2]. It was shown that using in vitro
propagation of the patient’s DC and their pul-
sing with tumor antigens from excised cancer§ This is an open-access article distributed under
the terms of the Creative Commons Attribution-
NonCommercial-No Derivative Works License,
which permits non-commercial use, distribution,
and reproduction in any medium, provided the
original author and source are credited.
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834 www.drugdiscoverytoday.com 1359-6446/tissues or cancer cell line lysate resulted in some
positive clinical outcomes [3,4]. For certain
subsets of particular cancers (i.e. castration-
resistant prostate cancer and melanoma),
therapy with ex vivo-activated patient’s per-
ipheral-blood mononuclear cells showed
improvement in survival and favorable immune
responses [5–7]. However, the therapeutic
effects observed are still far from most desirable
[6,8–12].
It has also become apparent that DC-based
therapy faces certain obstacles, the greatest of
which are: (i) the generation of a sufficient
number of functionally active DC in tumors, a
condition that the founding work [1] and later
analyses (e.g. [13]) have suggested to be
essential; and (ii) effective DC pulsing with real-
time tumor antigens [10,14].06/$ - see front matter  2014 The Author. Published by Elsevier LtdAnalysis and hypothesis
In theory, the predicaments outlined above [10,14]
are bigger than they appear. Available knowledge
inevitably predicts that any therapy with DC pulsed
in vitro by a genetically static population of tumor
antigens, followed by induction of tumor-specific
cytotoxic T cells, could kill only a fraction of the
tumor, because tumor cells continuously
mutate by their very nature, unpredictably
modifying tumor antigens. It is well known that
tumor cells mutate even when spreading in the
same organ, leading to selection of more
aggressive clones [15], which explains the het-
erogeneity of tumor-associated antigen
expression in primary tumors and metastases
[16]. Therefore, no matter what level of DC
priming is achieved with the current in vitro DC-
based therapeutic approach, it will never be. All rights reserved. http://dx.doi.org/10.1016/j.drudis.2014.02.008
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ease will always relapse. The entire history of
antibacterial therapy [17,18], chemotherapy
[19,20] and antibody-based cancer therapy [21]
has shown that it is not possible to outsmart cell
selection by being one step behind.
Another theoretical barrier of currently
implemented protocols with DC-based tumor
therapy is that none of the protocols has
incorporated an idea of intratumoral accumu-
lation of injected DC. However, this event is
logical for the induction of antitumor immunity
and was detailed as such in the founding work
[1]. Significant benefits of the intratumoral DC
injection versus a systemic DC injection were
shown in mouse tumor models [22]. However,
currently implemented protocols with ex vivo-
generated and systemically injected DC do not
suggest intratumoral DC retention and accu-
mulation. Current approaches do not provide
biologic mechanisms to facilitate intratumoral
DC retention, and, thereby, rule out the possi-
bility of intratumoral DC accumulation and a
tumor-specific response.
However, there is a theoretical solution to the
problem: let cancer cells orchestrate their own
killing as long as they exist. My hypothesis is
simple: make a stable transfection in situ of
tumor cells with a membrane-bound forms of
Flt3-L DNA [23] and GM-CSF DNA [24], so that
tumor cells always express membrane-bound
forms of Flt3 ligand and GM-CSF.
Adenoviral vector transfection, as the most
effective transfection method currently avail-
able, should be the best platform for transfec-
tion. High levels of expression and the presence
of membrane-bound Flt3-L and GM-CSF on
tumor cells would result in intratumoral homing,
propagation and maturation of DC, either from
peripheral blood DC progenitors [1] or from
resident DC [25]. Movement of attracted cells
through the gradient toward the higher con-
centration of chemokine is a well-known biolo-
gic phenomenon. Available data suggest that
there is an advantage of tumor-induced propa-
gation of DC compared with the systemic and
distant vaccination of ex vivo-derived DC [26].
Synergetic action of GM-CSF and Flt3-L on
dendropoiesis was shown in a mouse model [27].
There is also evidence that GM-CSF increases DC-
vaccine immune responses when administrated
repeatedly at low doses [28]. Tumor antigens
fused with GM-CSF were shown to activate ex
vivo autologous peripheral-blood mononuclear
cells, including antigen-presenting cells, and
elicited antitumor effects in humans [5,7]. The
intratumoral DC generated in this fashion will be
not a monolithic static cell line, but dynamicmatured DC subsets. After a high number of DC
are established, drug-induced apoptosis of some
tumor cells will assure a sufficient amount of
tumor antigens for pulsing intratumoral DC.
However, note that drug dosing and apoptotic
events in a tumor must not produce confluent
areas of apoptosis and necrosis. In such areas,
tumor vasculature always collapses, resulting in
the death of all cells, including DC; the same
collapse of tumor circulation also prevents
recruitment of DC progenitors from peripheral
blood and DC movement from tumor to lymph
nodes. By contrast, it has also been shown that
tumor transfection with Flt3-L gene, which is
followed by effective expression but is not
accompanied by drug-induced tumor apoptosis,
results only in a delay in tumor growth [29]. Both
persistent high concentrations of DC inside the
tumor and tumor apoptosis should result in DC
pulsing with real-time tumor-specific antigen.
Then, the already pulsed DC would be distributed
over multiple lymph nodes, similar to a distribu-
tion pattern shown after injection of ex vivo-
propagated DC [6] and initiate tumor-specific
CD4+ and CD8+ real-time responses. Moderate
chemotherapy to induced apoptosis could be
repeated as often as needed, because it is not
supposed to be toxic overall. Thus, no matter how
tumor cells mutate and differentiate, they would
always promote the homing, propagation and
maturation of DC, DC pulsing, specific antitumor
immunity and tumor cell killing (Patent pending).
It is also plausible that, with such treatment, a
natural barrier of protective antitumor immunity
could be restored, which is the main goal of DC-
based cancer therapy [30]. As to the choice of
drugs to induce tumor cell apoptosis, it depends
entirely on tumor sensitivity and immunomodu-
lation drug’s properties; relevant considerations in
regard to specific drugs and immune responses
are available [31–37].
Suggested models to test the hypothesis
In mice, the number of functional dendritic cells
is increased by multiple administration of Flt3-L
[38,39], augmenting DC density many fold.
Mouse cancer models have been used to test this
approach as an anticancer therapy. Experiments
showed that an increase in DC number (more
than 10-fold) has a significant antitumor effect
on pre-existing, poorly immunogenic tumors
[40,41]. It was also shown that GM-CSF stimu-
lates intratumoral DC to a stage suitable for
antigen priming and presentation [24].
Therefore, a simple experiment to test my
hypothesis could be conducted. Liver tumors,
generated, for example, by MC38 colon carci-
noma cells, could be transfected in situ with themembrane-bound form of Flt3-L and GM-CSF
DNA using an adenoviral platform. After intra-
tumoral DC propagation and maturation, che-
motherapy-induced tumor apoptosis would
provide sufficient amounts of tumor antigen for
DC pulsing. These manipulations should provide
sufficient distribution of DC, pulsed with real-
time tumor antigens, to lymph nodes and anti-
tumor immunity. Another protocol is based on
resection of part of the tumor, and the in vivo
transfection of tumor cells with Flt3-L and GM-
CSF DNA, followed by inoculation of the trans-
fected tumor cells back to the same organ of the
same animal. Further details of the suggested
protocols can be found in Supplemental material
online.
The choice of the above model is based on the
ability of the liver to recruit and propagate DC
[38,39,41], and the high density of resident DC
[25]. Mouse models of liver tumors are also
beneficial because hepatic artery delivery
enables sufficient liver tumor targeting [42].
Concluding remarks
What is now being faced in DC-based antitu-
mor therapy research is that practical imple-
mentations of this important concept appear
not to be satisfactory. Has it not always been
known that tumor cells always mutate and that
selection of phenotypes avoiding immuno-
surveillance is a fact? Yes! Has it not always
been known that DC-based cancer therapy
must be toward real-time antigens of live
tumor? Yes! Such facts are basic facts of cell
selection and evolution. In finding a cure for
cancer, one must not sidestep such biological
rules. I believe that the pronouncement
‘nothing in biology makes sense except in
the light of evolution’ [43] constitutes a
valuable scientific tool and not just a political
statement.
If the Flt3-L and GM-CSF group survives longer
than the control group, the hypothesis is correct
and in theory it would be possible to cure cancer
with DC-based therapy. If survival time does not
differ between groups, it is still worthwhile to
harvest liver and lymph nodes, immunostain
them for mature DC, CD4+ and CD8+ T cells and
determine whether Flt3-L- and GM-CSF-expres-
sing nonimmunogenic tumor cells can facilitate
DC maturation and sufficient tumor antigen
uptake in the tumor. If the intratumoral DC
maturation and antigen pulsing are achieved,
but there is no survival benefit, then the results
could be analyzed in terms of cancer immuno-
editing, tolerance, anergy and escape phenom-
ena. I omitted discussion of these phenomena
from this review on purpose, because ifwww.drugdiscoverytoday.com 835
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maturation, pulsing, CD4+ and CD8+ T cells did
not occur, then there is nothing to discuss.
Of course, stable tumor transfection in situ with
more than one gene constitutes a serious chal-
lenge in in vivo models of cancer. The experiment
with introducing to a cancer-bearing mouse a
significant population of Flt3-L- and GM-CSF-
expressing tumor cells is also difficult. Considering
that the doubling time of tumor mass in rodent
models is rapidly shortened in the progression of
multiple liver tumors [42,44], the window of
treatment opportunity might be too short for an
antitumor immune response. In this case, a con-
trolled limited number of tumors in the left lateral
lobe [2,3] and a single tumor in each of the median
lobes, using Matrigel [45] would be a better
model. However, no matter how difficult the
suggested experiments are, it is a practical chal-
lenge rather than a theoretical barrier.
The only theoretical impediment in this
hypothesis is the natural existence of cancer
stem cells within tumor cell populations, [46,47],
which also must be targeted to prevent relapse
[48]. Although, in theory, all cells in the tumor
would express Flt3-L and GM-CSF, and the tumor
would be saturated with DC, drug-induced
apoptosis of cancer stem cell is unlikely, because
of the low rate of cancer stem cell proliferation.
New approaches for targeting cancer stem cells
have been recently outlined [49]. Nevertheless, if
cancer stem cells start to differentiate toward
aggressive cones and proliferate, then they
would be a target.
Hypothesizing on a mouse model, I should
acknowledge potential reservations in regard to
the extrapolation of the mouse experiments to
the clinic, which are plenty. For a DC-based
antitumor approach, potential adverse effects
have been emphasized elsewhere (e.g. [50]). For
in situ adenoviral transfection, reservations are
notorious [51,52]. For introducing Flt3-L and GM-
CSF-expressing tumor cells back into a patient,
reservations are more than obvious: who could
suggest that injection of cancer cells to a patient
dying from the same cancer is an imaginable
procedure? However, who could imagine that
injection of bacteria causing the deadly disease
could prevent that same disease? Therefore, let
us try it first in mouse models and in mouse
experiments that have shaped many of the
innovations of modern medicine. If it works in
mouse, then there might be a chance and a good
reason to discuss the next step.
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